All In Biotech

Drugs by condition

Drugs approved for ankylosing spondylitis

Brand-name prescription drugs and biologics whose FDA label lists ankylosing spondylitis as an approved use. Matched on the label phrases: "ankylosing spondylitis", "axial spondyloarthritis".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

48

Still marketed, NDA or BLA

Drug classes

8

Novel drugs

14

New molecular entities and new biologics

In development

10

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for ankylosing spondylitis.

  • Vyscoxa (Celecoxib) · Carwin Pharm Assoc Jul 29, 2025
  • Rinvoq Lq (Upadacitinib) · Abbvie OrphanApr 26, 2024
  • Simlandi (Adalimumab-Ryvk) · Alvotech USA INC Feb 23, 2024
  • Idacio (Adalimumab-Aacf) · Fresenius Kabi USA Jan 5, 2024
  • Bimzelx (Bimekizumab-Bkzx) · Ucb INC NovelOct 17, 2023

All approved drugs for ankylosing spondylitis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 223 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Tumor Necrosis Factor Blocker (12)

  • Simponi Golimumab · Centocor Ortho Biotech INC · 2009
  • Cimzia Certolizumab Pegol · Ucb INC · 2008
  • Enbrel Etanercept · Immunex · 1998
  • Remicade Infliximab · Centocor INC · 1998
  • Yusimry Adalimumab-Aqvh · Emerge Bioscience Pte LTD · 2021
  • Avsola Infliximab-Axxq · Amgen INC · 2019
  • Hadlima Adalimumab-Bwwd · Samsung Bioepis CO LTD · 2019
  • Hyrimoz Adalimumab-Adaz · Sandoz INC · 2018
  • Renflexis Infliximab-Abda · Samsung Bioepis CO LTD · 2017
  • Amjevita Adalimumab-Atto · Amgen INC · 2016
  • Inflectra Infliximab-Dyyb · Celltrion INC · 2016
  • Simponi Aria Golimumab · Janssen Biotech · 2013

Nonsteroidal Anti-inflammatory Drug (6)

  • Celebrex Celecoxib · Upjohn · 1998
  • Vyscoxa Celecoxib · Carwin Pharm Assoc · 2025
  • Ec-Naprosyn Naproxen · Atnahs Pharma US · 1994
  • Naprosyn Naproxen · Atnahs Pharma US · 1987
  • Indocin Indomethacin · Cosette · 1985
  • Indomethacin Indomethacin · Chartwell Molecules · 1984

Interleukin-17A Antagonist (3)

  • Taltz Ixekizumab · Eli Lilly and CO · 2016
  • Cosentyx Secukinumab · Novartis Pharms Corp · 2015
  • Cosentyx Secukinumab · Novartis Pharms Corp · 2023

Corticosteroid (3)

  • Medrol Methylprednisolone · Pfizer · 1957
  • Kenalog-40 Triamcinolone Acetonide · Apothecon · 1965
  • Cortef Hydrocortisone · Pharmacia and Upjohn · 1952

Janus Kinase Inhibitor (2)

  • Rinvoq Upadacitinib · Abbvie · 2019
  • Rinvoq Lq Upadacitinib · Abbvie · 2024

Antirheumatic Agent (2)

  • Cuprimine Penicillamine · Valeant Pharms Intl · 1970
  • Depen Penicillamine · Mylan Speciality Lp · 1978

Adrenocorticotropic Hormone (2)

Class not listed in FDA's data (18)

  • Bimzelx Bimekizumab-Bkzx · Ucb INC · 2023
  • Xeljanz Tofacitinib Citrate · Pf Prism Cv · 2012
  • Humira Adalimumab · Abbvie INC · 2002
  • Celestone Soluspan Betamethasone Acetate, Betamethasone Sodium Phosphate · Organon · 1965
  • Simlandi Adalimumab-Ryvk · Alvotech USA INC · 2024
  • Idacio Adalimumab-Aacf · Fresenius Kabi USA · 2024
  • Yuflyma Adalimumab-Aaty · Celltrion · 2023
  • Xeljanz Tofacitinib Citrate · Pfizer · 2020
  • Hulio Adalimumab-Fkjp · Mylan Pharms INC · 2020
  • Abrilada Adalimumab-Afzb · Pfizer INC · 2019
  • Cyltezo Adalimumab-Adbm · Boehringer Ingelheim · 2017
  • Xeljanz Xr Tofacitinib Citrate · Pfizer · 2016
  • Orapred Odt Prednisolone Sodium Phosphate · Advanz Pharma · 2006
  • Naprelan Naproxen Sodium · Twi Pharms · 1996
  • Pediapred Prednisolone Sodium Phosphate · Pai Holdings · 1986
  • Depo-Medrol Methylprednisolone Acetate · Pfizer · 1959
  • Solu-Medrol Methylprednisolone Sodium Succinate · Pharmacia and Upjohn · 1959
  • Solu-Cortef Hydrocortisone Sodium Succinate · Pharmacia and Upjohn · 1955

Drugs in development for ankylosing spondylitis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • MK-7240PRA023, TulisokibartPhase 310 trials

    Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease

  • FilgotinibGS-6034, GLPG0634Phase 36 trials

    Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)

  • VC005Phase 35 trials

    Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis

  • Jaktinib HydrochloridePhase 34 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Atopic Dermatitis, Ankylosing Spondylitis

  • LNK01001Phase 33 trials

    Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis

  • SHR-1314Phase 33 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis

  • AK111Phase 32 trials

    Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis

  • HS_SW01 cellsHS_SW01Phase 23 trials

    Shenzhen Huishan Biotechnology Co., Ltd. · Ankylosing Spondylitis, Primary Ovarian Insufficiency (Poi), Systemic Sclerosis (SSc)

  • SPY002-072SPY072Phase 22 trials

    Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis

  • vilamakitugXB2001, NatrunixPhase 22 trials

    XBiotech, Inc. · Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA

More on ankylosing spondylitis: recruiting trials · published research

Related in immunology and inflammation: Rheumatoid arthritis · Plaque psoriasis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Lupus (SLE) · Hidradenitis suppurativa · Chronic hives (urticaria) · Alopecia areata

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.